ArticleiScience2026
Decomposition-driven biomarker identification enhances non-invasive early cancer detection.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accurate marker selection in cell-free DNA (cfDNA) is essential for non-invasive early cancer detection, yet conventional approaches based on bulk tissue data often yield markers with limited efficacy in blood-based assays, due to the sparse and heterogeneous nature of tumor-derived cfDNA released into the bloodstream during early tumorigenesis. Here, we present a component decomposition framework that leverages non-negative matrix factorization (NMF) to resolve distinct methylation components from bulk reduced representation bisulfite sequencing (RRBS) data of five gastrointestinal cancers and their para-carcinoma tissues. This approach demonstrates that cancer-specific signals can be recovered at the component level, enabling the identification of cancer-specific and tissue-of-origin markers with significantly improved performance in cfDNA. Extending this framework to transcriptomic data further validates its utility for cfRNA-based biomarker discovery and molecular subtyping. Together, our framework offers a robust and scalable solution to improve biomarker identification for early cancer detection and patient stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.